Optimized drug-coated balloon angioplasty of the superficial femoral and proximal popliteal arteries using the Tack Endovascular System: TOBA III 12-month results.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
11 2020
Historique:
received: 25 09 2019
accepted: 25 01 2020
pubmed: 18 5 2020
medline: 13 3 2021
entrez: 17 5 2020
Statut: ppublish

Résumé

The Tack Endovascular System (Intact Vascular, Wayne, Pa) combines low-metallic content with focal delivery to seal areas of dissection associated with balloon angioplasty. The device system is designed to treat vascular dissections in the superficial femoral and proximal popliteal arteries. Tack implants exert low radial force and are associated with minimal metal burden, which reduces the mechanical stress on the arterial wall in treating dissections after balloon angioplasty. This study investigated the safety and effectiveness of the Tack Endovascular System in patients with dissections after drug-coated balloon (DCB) angioplasty. The Tack Optimized Balloon Angioplasty III (TOBA III) study is a prospective, multicenter, single-arm study in which patients who underwent percutaneous transluminal angioplasty with the Medtronic IN.PACT Admiral DCB (Medtronic, Dublin, Ireland) and experienced dissection after angioplasty were treated with Tack implants. The primary end points were freedom from major adverse events at 30 days and primary patency at 12 months. A total of 201 patients were enrolled in the trial, 169 with standard-length lesions (≥20 mm and ≤150 mm) and 32 with long-length lesions (>150 mm and ≤250 mm). Safety and effectiveness results were favorable compared with historical benchmarks at 12 months in the standard-lesion cohort. Notably, patients in the standard-lesion cohort experienced 95.0% primary patency, 97.5% freedom from clinically driven target lesion revascularization, 100% freedom from amputation, and 100% survival at 12 months (P < .0001). Primary patency in long-lesion patients was 89.3%, freedom from clinically driven target lesion revascularization was 96.8%, and freedom from amputation was 100% at 12 months. Device success was achieved in 95.8% (182/190) and 97.7% (43/44) of devices deployed into standard-lesion and long-lesion patients, respectively. Procedural success was 99.4% (168/169) and 100% (44/44) in the standard-lesion and long-lesion cohorts, respectively, with only one bailout stent placed in the entire population. The Tack Endovascular System is a safe and effective treatment option for patients with dissections after angioplasty in the superficial femoral and proximal popliteal arteries, with high patency, low rates of secondary intervention, and low incidence of bailout stenting when it is used in combination with DCB.

Identifiants

pubmed: 32414527
pii: S0741-5214(20)30330-X
doi: 10.1016/j.jvs.2020.01.078
pii:
doi:

Substances chimiques

Coated Materials, Biocompatible 0

Banques de données

ClinicalTrials.gov
['NCT02802306']

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1636-1647.e1

Informations de copyright

Copyright © 2020. Published by Elsevier Inc.

Auteurs

Marianne Brodmann (M)

Division of Angiology, Medical University Graz, Graz, Austria. Electronic address: marianne.brodmann@medunigraz.at.

Christian Wissgott (C)

Institute for Diagnostic and Interventional Radiology, Westküstenklinikum Heide, Heide, Germany.

Klaus Brechtel (K)

Interventional Radiology, Franziskus-Hospital Berlin, Berlin, Germany.

Sigrid Nikol (S)

Clinical and Interventional Angiology, Asklepios Klinik St. Georg, Hamburg, Germany.

Thomas Zeller (T)

Department of Angiology, Universitats-Herzzentrum, Bad Krozingen, Germany.

Michael Lichtenberg (M)

Clinic of Angiology, Karolinen-Hospital, Arnsberg, Germany.

Erwin Blessing (E)

Vascular Clinic, Klinikum Karlsbad Langensteinbach, Karlsbad, Germany.

William Gray (W)

Division of Cardiovascular Disease, Lankenau Heart Institute, Philadelphia, Pa.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH